$8.09
+0.07 (+0.87%)
NIQ News6 articles
Needham Adjusts NIQ Target Amid Sector Valuation Reset, Focus on 2026 Margin Plan
NIQ Global Intelligence stock remained flat in premarket trading following a price target reduction by Needham, which cited lower sector multiples. The company's detailed 2026 margin expansion and restructuring plans are drawing investor attention.
NIQ Shares Steady as Needham Adjusts Target, Focus Shifts to 2026 Margin Plan
NIQ Global Intelligence shares remained unchanged in premarket trading following a price target reduction by Needham. Investors are focusing on the company's detailed 2026 profitability and restructuring roadmap.
NIQ Shares Steady as Needham Adjusts Target, Focus Shifts to 2026 Margin Goals
NIQ Global Intelligence shares were unchanged in premarket trading following a price target reduction by Needham. The firm remains bullish, citing the company's detailed 2026 profitability roadmap.
UniQure Holds Gains as FDA Signals Path for Huntington's Gene Therapy Filing
UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.
FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy
uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.
uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.